top of page
  • Patient Education

Patient Education: Ciltacabtagene Autoleucel - Carvykti - (CART Cell Therapy) - Immunotherapy

Updated: Jan 27

CILTA CEL CART Cell therapy Multiple Myeloma

Ciltacabtagene Autoleucel ( Carvykti)

FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma

On February 28, 2022, the Food and Drug Administration approved ciltacabtagene autoleucel (CARVYKTI, Janssen Biotech, Inc.) for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody.

Safety and efficacy were evaluated in CARTITUDE-1 (NCT03548207), an open label, multicenter clinical trial evaluating ciltacabtagene autoleucel in 97 patients with relapsed or refractory multiple myeloma who received at least three prior lines of therapy which included a PI, an IMiD, and an anti-CD38 monoclonal antibody and who had disease progression on or after the last chemotherapy regimen; 82% had received four or more prior lines of antimyeloma therapy.

Learn more:


Information on Carvykti website



CARVYKTI (ciltacabtagene autoleucel)

IMF Understanding Series

IMF Resource Library

Current FDA-Approved Medications for Multiple Myeloma Treatment



Janssen's Cilta-Cel CAR T Receives FDA Approval for Relapsed Multiple Myeloma

HealthTree University for Multiple Myeloma Lectures

Health Tree University Myeloma Videos



Standard Treatments - BCMA-directed personalized immunotherapy - ciltacabtagene autoleucel or cilta-cel - Carvykti

MMRF Education Programs

MMRF Videos


References CARVYKTI- ciltacabtagene autoleucel injection, suspension:

FDA Label Prescribing Information (Revised 03/2022)

Drug Label Information at DAILYMED - NIH-National Library of Medicine

Other Resources


- Multiple Myeloma Patient Education & Information on ongoing Multiple Myeloma Clinical Trials -

* Belantamab mafodotin (Withdrawn from United States market)


Posts Archive
bottom of page